The FDA issued warning letters to multiple compounding pharmacies in early 2025, citing violations related to retatrutide and AOD-9604. The letters mark a sharp enforcement turn after months of quality concerns swirling around compounded GLP-1 receptor agonists. Three compounding facilities received citations for producing retatrutide, a triple-hormone receptor agonist still in Phase 3 trials, without adequate sterility assurance or valid prescriptions. The agency also flagged AOD-9604, a peptide fragment of human growth hormone, for being compounded with insufficient evidence of safety or efficacy. This crackdown follows a 2024 study that found potency and purity failures in compounded semaglutide and tirzepatide samples.
The warning letters represent a significant escalation in FDA oversight of compounding-grade peptides. For years, the agency focused enforcement on traditional small-molecule drugs. Now, it is turning its attention to the burgeoning market for custom-made peptide preparations. The letters cite specific violations under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. They also reference USP compounding standards, particularly USP <797> for sterile preparations. This regulatory shift has immediate implications for compounding pharmacies, telehealth platforms, and patients seeking access to these novel agents.
The News: Warning Letters Detail Specific Violations
The FDA's warning letters, dated February and March 2025, outline three primary areas of concern. First, the pharmacies compounded retatrutide using active pharmaceutical ingredients that lacked a USP or NF monograph. This violates the statutory requirement that bulk drug substances used in compounding must have a recognized standard for quality and purity. Second, the facilities failed to conduct adequate sterility testing on finished preparations. One letter noted that the pharmacy released batches for distribution before receiving final sterility test results. Third, the agency cited the compounding of AOD-9604 for sublingual and injectable use without any FDA-approved new drug application or sufficient clinical evidence to support its safety.
The letters also highlight the absence of valid patient-specific prescriptions for many compounded retatrutide orders. This is a critical distinction between 503A compounding, which requires individual prescriptions, and 503B outsourcing facilities, which can compound in larger batches. The FDA determined that the pharmacies were effectively manufacturing unapproved new drugs under the guise of compounding. This is a 3 of 5 on the evidence quality scale for regulatory action, given the clear statutory language and the documented inspectional findings. The agency gave the pharmacies 15 working days to respond with corrective actions.
Context: A History of Quality Concerns in Compounded GLP-1s
The retatrutide crackdown did not emerge in a vacuum. It follows a series of quality failures in compounded GLP-1 receptor agonists that have drawn intense scrutiny. A 2024 study published in the Journal of the American Pharmacists Association analyzed compounded semaglutide samples from multiple pharmacies. The researchers found that 34% of samples fell outside the acceptable potency range of 90% to 110% of labeled strength. Some samples contained as little as 62% of the declared semaglutide content. Others showed elevated levels of a known impurity, B28-isoAsp, which can form during improper peptide synthesis or storage.
These findings prompted the FDA to issue a public warning in October 2024 about the risks of compounded GLP-1s. The agency noted that it had received adverse event reports including dosing errors, injection site reactions, and gastrointestinal side effects potentially linked to potency variations. The quality study, which we covered in detail in our article on retatrutide compounding under fire after the GLP-1 quality study, also raised concerns about sterility. Two samples tested positive for microbial contamination, though the study authors cautioned that the sample size was limited. This is a 2 of 3 on evidence quality, as the study was not designed to establish a causal link between quality failures and patient harm.
Meanwhile, the clinical trial landscape for retatrutide has been advancing rapidly. A 2023 Phase 2 trial published in The New England Journal of Medicine demonstrated that retatrutide produced up to 24.2% weight loss at 48 weeks in people with obesity. This efficacy data fueled demand for compounded versions, as patients sought access before FDA approval. However, the trial also highlighted the complexity of retatrutide's mechanism, which targets GLP-1, GIP, and glucagon receptors. This triple agonism raises the bar for compounding precision, as even minor errors in peptide sequence or folding could alter receptor selectivity. Our analysis of retatrutide trial data and its regulatory implications for compounding pharmacies noted that the FDA would likely prioritize enforcement against unapproved retatrutide preparations given the drug's novelty and potency.
What It Means: A Regulatory Shift with Broad Implications
The warning letters signal a new phase in FDA enforcement against compounding of unapproved peptides. There are three key takeaways. 1) The agency is now treating retatrutide as a high-risk compound due to its investigational status and complex pharmacology. 2) The inclusion of AOD-9604 in the warning letters indicates that the FDA is scrutinizing a wider range of peptides beyond the GLP-1 class. 3) The citations for sterility failures and lack of valid prescriptions suggest that the agency is applying traditional compounding enforcement tools to the peptide space.
For compounding pharmacies, the letters serve as a clear warning. The FDA expects strict adherence to USP <797> standards for sterile compounding, including environmental monitoring, personnel training, and finished product testing. Pharmacies that compound retatrutide or AOD-9604 without meeting these standards face regulatory action, up to and including seizure of products and injunctions. The letters also make clear that the FDA considers these peptides to be unapproved new drugs when compounded without valid prescriptions or in large quantities. This interpretation could expose pharmacies to charges of manufacturing and distributing unapproved drugs, which carry significant legal and financial penalties.
The regulatory shift also affects telehealth platforms and prescribers. Many compounded retatrutide prescriptions originate from online consultations where the patient-provider relationship may be minimal. The FDA has previously warned about the risks of prescribing compounded drugs without adequate patient evaluation. The new warning letters reinforce that expectation. Prescribers who authorize compounded retatrutide for patients they have not examined in person could face scrutiny from state medical boards and the FDA. This is a 4 of 5 on the evidence quality scale for regulatory risk, given the clear statutory requirements and the agency's recent enforcement posture.
Who's Affected: Pharmacies, Patients, and the Peptide Supply Chain
The immediate impact falls on the compounding pharmacies that received warning letters. These facilities must now implement corrective actions, which may include recalling distributed products, revising standard operating procedures, and conducting retrospective sterility testing. Failure to respond adequately could lead to more severe enforcement, such as product seizures or consent decrees. The broader compounding industry is also affected, as the letters set a precedent for how the FDA will evaluate peptide compounding operations. Pharmacies that compound other investigational peptides, such as Vesugen or IGF-1 LR3, should review their practices in light of the FDA's expectations.
Patients who rely on compounded retatrutide for weight management face uncertainty. If pharmacies halt production in response to the warning letters, access to these preparations could diminish. Patients may turn to unregulated sources, such as online peptide vendors, which carry even greater risks of contamination and mislabeling. The FDA has warned consumers about the dangers of purchasing peptides from unlicensed sources, but the demand for retatrutide remains high. The agency's enforcement actions may inadvertently drive patients toward riskier alternatives if legitimate compounding options disappear.
The peptide supply chain is also under pressure. The warning letters highlight the FDA's concern about the quality of active pharmaceutical ingredients used in compounding. Many compounding pharmacies source retatrutide and AOD-9604 from overseas manufacturers that may not comply with current good manufacturing practices. The FDA expects pharmacies to verify the quality of their bulk drug substances through certificates of analysis and independent testing. This requirement could strain smaller compounding operations that lack the resources for rigorous supplier qualification. The agency's focus on ingredient quality may lead to consolidation in the compounding peptide market, with larger 503B outsourcing facilities gaining an advantage.
Other peptides in the compounding pipeline, such as oxytocin, PT-141, and IGF-1 LR3, could also face increased scrutiny. While the warning letters did not specifically cite these compounds, the FDA's enforcement principles apply broadly. Any peptide that is not the subject of an FDA-approved new drug application and is compounded without adequate quality controls could be targeted. Pharmacies that compound oxytocin for off-label uses, such as autism or anxiety, should ensure they have valid prescriptions and meet USP standards. Similarly, PT-141, which is approved as Vyleesi for hypoactive sexual desire disorder, is subject to specific compounding restrictions. The FDA has not yet issued guidance on compounding PT-141, but the warning letters suggest a more aggressive enforcement posture is coming.
What to Watch Next: Enforcement Trends and Policy Developments
The FDA's next steps will be critical in shaping the compounding peptide landscape. The agency could issue additional warning letters to other pharmacies, expand its inspection program to include more peptide compounds, or publish formal guidance on compounding of GLP-1 receptor agonists and related peptides. A 2022 review in the Journal of Law and the Biosciences noted that the FDA has historically used warning letters as a first step in a graduated enforcement approach. If pharmacies do not comply, the agency may escalate to product seizures, injunctions, or even criminal referrals in cases of intentional misconduct.
Congressional interest in compounded peptides is also growing. In late 2024, a bipartisan group of lawmakers sent a letter to the FDA requesting information on the agency's oversight of compounded GLP-1s. The letter cited the quality study findings and asked whether additional legislative authority was needed to protect patients. The FDA's response, which is expected in mid-2025, could signal whether the agency will seek new statutory tools to regulate peptide compounding. Some industry observers have called for a mandatory registration system for compounding pharmacies that produce high-risk peptides, similar to the 503B outsourcing facility registration.
State boards of pharmacy are also likely to become more active. Several states have already issued their own warnings about compounded GLP-1s, and the FDA's action may prompt more states to inspect compounding pharmacies and take disciplinary action. The National Association of Boards of Pharmacy has been tracking the issue and may develop model regulations for peptide compounding. This patchwork of state and federal enforcement could create compliance challenges for pharmacies that operate across state lines.
The compounding peptide market is at a crossroads. The FDA's warning letters make clear that the era of lax oversight is ending. Pharmacies that want to continue compounding retatrutide, AOD-9604, and similar peptides will need to invest in quality systems, ingredient verification, and patient-specific prescription management. Those that cannot meet these standards may exit the market or shift to other products. Patients and prescribers should stay informed about the regulatory landscape and prioritize safety when considering compounded peptides. The coming months will reveal whether the FDA's enforcement actions are sufficient to address the quality concerns or whether more fundamental reforms are needed.
Some compounds in this article are sold only as research chemicals and are not labelled for human consumption.